APRI (Aprinoia Therapeutics) Treasury Stock: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Treasury Stock?

Aprinoia Therapeutics APRI Treasury Stock is $0.00 Mil as of Dec. 2023.

Treasury stock is the portion of shares that a company keeps in their own treasury. Aprinoia Therapeutics's treasury stock for the quarter that ended in Dec. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Aprinoia Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Treasury Stock Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Treasury Stock
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Treasury Stock 0.00 0.00 0.00 0.00 0.00

Aprinoia Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Treasury Stock of $0.00 Mil as of Dec. 2023. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Treasury Stock too high?
Aprinoia Therapeutics' current Treasury Stock is $0.00 Mil.
How does Aprinoia Therapeutics' Treasury Stock compare to ?
Aprinoia Therapeutics' Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Treasury Stock is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.